Filamentous Hemagglutinin, C-terminal Domain (rC-FHA)

Filamentous Hemagglutinin, C-terminal Domain (rC-FHA), Recombinant from Bordetella pertussis

Catolog #



964-900 50 μg Inquire
964-910 200 μg Inquire
964-920 1 mg Inquire
964-930 > 5 mg Inquire

Recombinant C-FHA is supplied in PBS (pH 7.4), 50% glycerol at a desired concentration of 0.1 to 0.5 mg/ml.

Filamentous hemaglutinin (FHA) is a major adhesin of B. pertussis and is a component of most acellular pertussis vaccines. FHA is produced from a 367-kD precursor. The first 71 amino acids comprise a signal peptide, which is removed by proteolysis. FHA is further processed by the SphB1 protease resulting in the 220-kD N-terminal region that is traditionally known as FHA. Much of this form of FHA is secreted from the cell. The C-terminal 130-kD portion (designated herein as C-FHA) remains associated with the B. pertussis cell and is not included in acellular pertussis vaccines.

A DNA fragment encoding amino acids 2373-3590 of the FHA gene is PCR amplified from B. pertussis BP338 and cloned into a pET expression vector. The resulting construct generates a recombinant form of C-FHA with a His tag at the N-terminus. The recombinant protein is expressed in E. coli strain BL21(DE3) and purified from inclusion bodies.

Store at -20°C. To insure uniformity, it is recommended that the C-FHA suspension be swirled or gently mixed prior to use.

Protein Content
Protein concentration was determined by Bradford assay method using bovine serum albumin as standard.

>95% by SDS-PAGE.

Quality control documentation of each lot is provided with shipment.